A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The main objectives of the current study are to establish the safety and clinical
proof-of-concept of NC-503 in inadequately controlled patients with Type 2 diabetes and
features of metabolic syndrome treated with either metformin, a sulfonylurea agent, or
metformin in combination with a sulfonylurea agent.